Belpointe Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Belpointe Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-836	Closed	-$81.3K	–	917
2023 Q1	$81.3K	Sell	836 -528	-39%	-$54.7K	﹤0.01%	1432
2022 Q4	$141K	Sell	1,364 -92	-6%	-$8.64K	0.01%	1052
2022 Q3	$124K	Buy	1,456 +15	+1%	+$1.34K	0.01%	1044
2022 Q2	$119K	Sell	1,441 -269	-16%	-$21.4K	0.01%	1031
2022 Q1	$132K	Buy	1,710 +38	+2%	+$3.18K	0.01%	1087
2021 Q4	$148K	Sell	1,672 -836	-33%	-$69K	0.01%	1019
2021 Q3	$194K	Sell	2,508 -102	-4%	-$8.05K	0.01%	869
2021 Q2	$218K	Sell	2,610 -66	-2%	-$5.23K	0.02%	803
2021 Q1	$202K	Buy	2,676 +201	+8%	+$16.4K	0.02%	747
2020 Q4	$217K	Buy	+2,475	New	+$196K	0.02%	670
2020 Q3	–	Sell	-1,568	Closed	-$193K	–	781
2020 Q2	$193K	Sell	1,568 -4,243	-73%	-$422K	0.03%	535
2020 Q1	$491K	Buy	+5,811	New	+$501K	0.09%	246

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Belpointe Asset Management's BMRN Position: Q2 2023 in Review

Belpointe Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 836 shares — an estimated $81.3K sold.

Belpointe Asset Management first reported a position in BMRN in Q1 2020 and held it in 12 quarters. The position peaked at $491K in Q1 2020. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

Belpointe Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 836 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $81.3K.
Belpointe Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2020 and held it in 12 quarters.
Belpointe Asset Management's BioMarin Pharmaceuticals position peaked at $491K in Q1 2020.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.